The Mass Spectrometry society of Japan - The 68th Annual Conference on Mass Spectrometry, Japan
Japanese

Abstract

Table of contents

Timetable

Plenary Lectures

Oral Sessions (Day1, Day2, Day3)

Poster Presentations (Day1, Day2, Day3)

Workshops

Luncheon Seminars (Day1, Day2, Day3)

Poster Presentations

Day 3, May 13（Wed.）　　Poster (1008/09)

3P-13　　PDF

Examination of pretreatment and separation conditions for quantification of abiraterone and its metabolites in human serum by LC/MS

(1Mukogawa Women's Univ., 2Mukogawa Women's Univ.)
Hiromi Kanji1, oShizuyo Horiyama2, Jun Haginaka1,2

Abiraterone (Abi) is used for the treatment of castration-resistant prostate cancer. Abi is metabolized to a more active Δ4-abiraterone (D4A) than Abi by 3β-hydroxysteroid dehydrogenase and further D4A is metabolized to keto-5α- and keto-5β-Abi by 5α- and 5β-reductases, respectively. Furthermore, keto-Abi’s are metabolized to their hydroxy metabolites, 3α-OH-5α-Abi and 3β-OH-5α-Abi, and 3-keto-5β-Abi and 3β-OH-5β-Abi. In this study, we examined the pretreatment and separation conditions for Abi and its seven metabolites in human serum for their quantification. A Zorbax Eclipse plus C18 column showed the best separation for them among the C18 columns tested. A silica-based Strata-Si solid-phase extraction column gave the best recovery and the lowest matrix effect among the pretreatment methods used. The analytes were quantified using extracted ion chromatograms obtained by Q-TOF mass spectrometer under the optimal pretreatment and separation conditions.